Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW FY2015 Budget Request to Center on PM Abe’s Growth Strategy
July 22, 2014
- ICH M7 Guideline Reaches Step 4; MHLW to Issue Notification
July 22, 2014
- Ministry Panel Agrees to Add Kitasato Daiichi Sankyo Vaccine’s Squarekids to Routine Vaccine Program
July 18, 2014
- Post-Shipment Quality Control Testing of Radiopharmaceuticals Would Not Violate GMP: MHLW
July 18, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 2: Prof. Kageyama of Jikei Univ.
July 18, 2014
- MOF Official in Charge of Health Spending to “Carefully” Discuss Budgets
July 17, 2014
- Council OKs Public-Knowledge Based Application for Oxaliplatin at Doses Approved Overseas
July 16, 2014
- 50% Price Rule, Unifying Price Brackets Starters of Next Generic Price Revision Discussions: Ministry Official
July 15, 2014
- MHLW Panel to Elaborate Proposed Scheme to Broaden Drug Development Requests
July 15, 2014
- Editor’s Pick: Five Healthcare News Headlines for June 30 - July 11
July 14, 2014
- Revised PAL to Go Live on November 25: Ministry Exec
July 14, 2014
- Science Ministry’s Updated Guidelines to Require Research Data Preservation
July 14, 2014
- Draft Policy on Resource Allocation Focuses Funding on 9 Fields of Healthcare R&D
July 14, 2014
- Is Legal Regulation Necessary? Clinical Research at Turning Point 1: TRI Director Fukushima
July 14, 2014
- Unami Tapped as New Budget Examiner for Health Finances
July 11, 2014
- PFSB Announces Final Draft of Drug Interaction Guidelines
July 11, 2014
- Utsunomiya to Move to National Center for Global Health and Medicine
July 10, 2014
- MHLW Orders Revisions of Precaution Statements for a Number of Drugs Including Forteo and Paxil
July 10, 2014
- MHLW Releases Report on Medical Database Project
July 9, 2014
- Doctors at Ryukaikon Council Request Mandatory Inclusion of Expiry Dates in Product Barcodes
July 8, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…